ScholarLens Back to search
2007•Zhongguo linchuang yaolixue yu zhiliaoxueRequires access

Recent advance in association between genetic polymorphisms in CYP2C9 and pharmacokinetics and pharmacodynamics of sulphonylureas

Min Huang

Open publisher page 0 citations

Abstract

Sulphonylureas are the initial and most commonly used therapy for type 2 diabetes mellitus.Sulphonylureas are metabolized by CYP2C9,and the CYP2C9 gene has several mutant alleles leading to genetic polymorphisms in humans.The variation of metabolism abilities of different CYP2C9 genotype is one of the reasons why the type 2 diabetes mellitus patients need different doses of sulphonylureas.To offer a guidance for individualizing administration of sulphonylureas,we specify the relationship between genetic polymorphisms in CYP2C9 and the pharmacokinetics and pharmacodynamics of sulphonylureas.

About this research paper

What this paper is about

Sulphonylureas are the initial and most commonly used therapy for type 2 diabetes mellitus.Sulphonylureas are metabolized by CYP2C9,and the CYP2C9 gene has several mutant alleles leading to genetic polymorphisms in humans.The variation of metabolism abilities of different CYP2C9 genotype is one of the reasons why the type 2 diabetes mellitus patients need different doses of sulphonylureas.To offer a guidance for individualizing administration of sulphonylureas,we specify the relationship between genetic polymorphisms in CYP2C9 and the pharmacokinetics and pharmacodynamics of sulphonylureas.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Sulphonylureas are the initial and most commonly used therapy for type 2 diabetes mellitus.Sulphonylureas are metabolized by CYP2C9,and the CYP2C9 gene has several mutant alleles leading to genetic polymorphisms in humans.The variation of metabolism abilities of different CYP2C9 genotype is one of the reasons why the type 2 diabetes mellitus patients need different doses of sulphonylureas.To offer a guidance for individualizing administration of sulphonylureas,we specify the relationship between genetic polymorphisms in CYP2C9 and the pharmacokinetics and pharmacodynamics of sulphonylureas.

Key concepts: CYP2C9, Pharmacodynamics, Pharmacokinetics, Pharmacology, Pharmacogenetics, Medicine, Type 2 Diabetes Mellitus, Genotype

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Recent advance in association between genetic polymorphisms in CYP2C9 and pharmacokinetics and pharmacodynamics of sulphonylureas — Research Paper | ScholarLens